Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR
- 15 July 2023
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (10) , 1157-1159
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC011417 02)
- Gilead Sciences (CRADA 3019)
- CRADA with Kite Pharma, a Gilead company
This publication has 12 references indexed in Scilit:
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesBlood, 2021
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyJournal of Clinical Oncology, 2020
- Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.Journal of Clinical Oncology, 2020
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialJournal of Clinical Oncology, 2020
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaNature Medicine, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane DomainsMolecular Therapy, 2017
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansTransplantation and Cellular Therapy, 2010